{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T12:52:03Z","timestamp":1787748723392,"version":"build-2784847793"},"reference-count":40,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"45","license":[{"start":{"date-parts":[[2021,11,12]],"date-time":"2021-11-12T00:00:00Z","timestamp":1636675200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Objectives:<\/jats:title>\n            <jats:p>The purpose of this meta-analysis was to evaluate the efficacy and safety of tibial nerve stimulation (TNS) versus antimuscarinic agents in the management of overactive bladder (OAB) syndrome.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>The databases MEDLINE, EMBASE, the Cochrane Controlled Trial Register of Controlled Trials from 2000 to May 2021 were searched to identify randomized controlled trials that referred to the use of TNS and antimuscarinic agents for the treatment of OAB syndrome. A systematic review and meta-analysis was conducted.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Eight publications involving 420 patients were included in the meta-analysis. In the analysis, we found TNS had a comparable effect with antimuscarinic agents on micturition per day, nocturia, urge incontinence, and voided volume (<jats:italic toggle=\"yes\">P<\/jats:italic>\u200a=\u200a.9; .4; .78; .44, respectively). Scores measured by questionnaires Overactive Bladder Symptom Score and Overactive Bladder questionnaire Short Form items also indicated no statistical difference between 2 groups. TNS group had a significantly less discontinuation rate and adverse events (<jats:italic toggle=\"yes\">P<\/jats:italic>\u200a=\u200a.003; .0001).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>TNS is as effective as antimuscarinic agents for the treatment of OAB. Moreover, TNS appears to be more tolerable and safer than antimuscarinic agents.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000027745","type":"journal-article","created":{"date-parts":[[2021,11,12]],"date-time":"2021-11-12T14:07:33Z","timestamp":1636726053000},"page":"e27745","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":5,"title":["Pooled analysis of the efficacy and safety of tibial nerve stimulation versus antimuscarinic agents in the management of overactive bladder syndrome"],"prefix":"10.1097","volume":"100","author":[{"given":"Liping","family":"Xia","sequence":"first","affiliation":[{"name":"Department of Neurology, Weifang Traditional Chinese Medicine Hospital, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huilei","family":"Yan","sequence":"additional","affiliation":[{"name":"Department of Urology, Liaocheng People's Hospital, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yalei","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Ultrasound, Weifang People's Hospital, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Urology, Weifang People's Hospital, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yudong","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Urology, Weifang People's Hospital, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7714-7869","authenticated-orcid":false,"given":"Zhipeng","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Urology, Weifang People's Hospital, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunye","family":"Su","sequence":"additional","affiliation":[{"name":"Department of Urology, Weifang People's Hospital, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2021,11,12]]},"reference":[{"key":"R1-20250504","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s00192-016-3123-4","article-title":"An International Urogynecological Association (IUGA)\/International Continence Society (ICS) joint report on the terminology for the conservative and nonpharmacological management of female pelvic floor dysfunction","volume":"28","author":"Bo","year":"2017","journal-title":"Int Urogynecol J"},{"key":"R2-20250504","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s00345-002-0301-4","article-title":"Prevalence and burden of overactive bladder in the United States","volume":"20","author":"Stewart","year":"2003","journal-title":"World J Urol"},{"key":"R3-20250504","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1111\/luts.12193","article-title":"Prevalence of overactive bladder in China, Taiwan and South Korea: results from a cross-sectional, population-based study","volume":"11","author":"Chuang","year":"2019","journal-title":"Low Urin Tract Symptoms"},{"key":"R4-20250504","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1016\/j.eururo.2006.09.019","article-title":"Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study","volume":"50","author":"Irwin","year":"2006","journal-title":"Eur Urol"},{"key":"R5-20250504","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1097\/JU.0000000000000309","article-title":"Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA\/SUFU guideline amendment 2019","volume":"202","author":"Lightner","year":"2019","journal-title":"J Urol"},{"key":"R6-20250504","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.mayocp.2019.11.024","article-title":"Evaluation and treatment of overactive bladder in women","volume":"95","author":"Raju","year":"2020","journal-title":"Mayo Clin Proc"},{"key":"R7-20250504","first-page":"S150","article-title":"Treatment of overactive bladder: a model comparing extended-release formulations of tolterodine and oxybutynin","volume":"11","author":"Perfetto","year":"2005","journal-title":"Am J Manag Care"},{"key":"R8-20250504","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1185\/030079907X159533","article-title":"Impact of overactive bladder on women in the United States: results of a national survey","volume":"23","author":"Dmochowski","year":"2007","journal-title":"Curr Med Res Opin"},{"key":"R9-20250504","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1097\/AOG.0b013e31818e8aa4","article-title":"Discontinuation rates of anticholinergic medications used for the treatment of lower urinary tract symptoms","volume":"112","author":"Gopal","year":"2008","journal-title":"Obstet Gynecol"},{"key":"R10-20250504","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/S0022-5347(05)68558-8","article-title":"Sacral nerve stimulation for treatment of refractory urinary urge incontinence. Sacral Nerve Stimulation Study Group","volume":"162","author":"Schmidt","year":"1999","journal-title":"J Urol"},{"key":"R11-20250504","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1002\/nau.20360","article-title":"Management of refractory urinary urge incontinence following urogynecological surgery with sacral neuromodulation","volume":"26","author":"Starkman","year":"2007","journal-title":"Neurourol Urodyn"},{"key":"R12-20250504","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1046\/j.1464-410x.2001.02219.x","article-title":"Neuromodulation techniques in the treatment of the overactive bladder","volume":"87","author":"Groen","year":"2001","journal-title":"BJU Int"},{"key":"R13-20250504","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/S0022-5347(05)65863-6","article-title":"Posterior tibial nerve stimulation as neuromodulative treatment of lower urinary tract dysfunction","volume":"166","author":"van Balken","year":"2001","journal-title":"J Urol"},{"key":"R14-20250504","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/1471-2490-13-61","article-title":"Percutaneous Tibial Nerve Stimulation (PTNS) efficacy in the treatment of lower urinary tract dysfunctions: a systematic review","volume":"13","author":"Gaziev","year":"2013","journal-title":"BMC Urol"},{"key":"R15-20250504","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.eururo.2017.11.002","article-title":"Efficacy and safety of sacral and percutaneous tibial neuromodulation in non-neurogenic lower urinary tract dysfunction and chronic pelvic pain: a systematic review of the literature","volume":"73","author":"Tutolo","year":"2018","journal-title":"Eur Urol"},{"key":"R16-20250504","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/j.juro.2009.05.045","article-title":"Randomized trial of percutaneous tibial nerve stimulation versus extended-release tolterodine: results from the overactive bladder innovative therapy trial","volume":"182","author":"Peters","year":"2009","journal-title":"J Urol"},{"key":"R17-20250504","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1159\/000350216","article-title":"Solifenacin succinate versus percutaneous tibial nerve stimulation in women with overactive bladder syndrome: results of a randomized controlled crossover study","volume":"75","author":"Vecchioli-Scaldazza","year":"2013","journal-title":"Gynecol Obstet Invest"},{"key":"R18-20250504","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s00345-013-1112-5","article-title":"Prospective and randomized comparison of electrical stimulation of the posterior tibial nerve versus oxybutynin versus their combination for treatment of women with overactive bladder syndrome","volume":"32","author":"Souto","year":"2014","journal-title":"World J Urol"},{"key":"R19-20250504","doi-asserted-by":"crossref","first-page":"208","DOI":"10.5152\/tud.2015.94210","article-title":"Role of percutaneous posterior tibial nerve stimulation either alone or combined with an anticholinergic agent in treating patients with overactive bladder","volume":"41","author":"Kizilyel","year":"2015","journal-title":"Turk J Urol"},{"key":"R20-20250504","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.ejogrb.2015.05.014","article-title":"Percutaneous tibial nerve stimulation versus tolterodine for overactive bladder in women: a randomised controlled trial","volume":"191","author":"Preyer","year":"2015","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"R21-20250504","doi-asserted-by":"crossref","first-page":"06","DOI":"10.1016\/j.ejogrb.2015.09.020","article-title":"Transcutaneous posterior tibial nerve stimulation versus extended release oxybutynin in overactive bladder patients. A prospective randomized trial","volume":"196","author":"Manr\u00edquez","year":"2016","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"R22-20250504","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1590\/s1677-5538.ibju.2016.0611","article-title":"Effectiveness and durability of solifenacin versus percutaneous tibial nerve stimulation versus their combination for the treatment of women with overactive bladder syndrome: a randomized controlled study with a follow-up of ten months","volume":"44","author":"Vecchioli-Scaldazza","year":"2018","journal-title":"Int Braz J Urol"},{"key":"R23-20250504","doi-asserted-by":"crossref","first-page":"271","DOI":"10.5644\/ama2006-124.267","article-title":"Effects of treating an overactive urinary bladder in patients with multiple sclerosis","volume":"48","author":"Zoni\u0107-Imamovi\u0107","year":"2019","journal-title":"Acta Med Acad"},{"key":"R24-20250504","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"R25-20250504","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"R26-20250504","first-page":"401","article-title":"Statistical analysis of data from clinical and retrospective studies","volume":"138","author":"Blunch","year":"1976","journal-title":"Ugeskr Laeger"},{"key":"R27-20250504","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1002\/(SICI)1097-0258(19960630)15:12<1237::AID-SIM301>3.0.CO;2-N","article-title":"Meta-analysis in the design and monitoring of clinical trials","volume":"15","author":"DerSimonian","year":"1996","journal-title":"Stat Med"},{"key":"R28-20250504","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1080\/13697137.2018.1552254","article-title":"Managing overactive bladder","volume":"22","author":"Robinson","year":"2019","journal-title":"Climacteric"},{"key":"R29-20250504","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1016\/j.juro.2015.01.087","article-title":"Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA\/SUFU guideline amendment","volume":"193","author":"Gormley","year":"2015","journal-title":"J Urol"},{"key":"R30-20250504","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1007\/s00192-016-3258-3","article-title":"Anticholinergic prescription: are healthcare professionals the real burden?","volume":"28","author":"Araklitis","year":"2017","journal-title":"Int Urogynecol J"},{"issue":"(Suppl 3)","key":"R31-20250504","first-page":"S50","article-title":"Is coexistent overactive-underactive bladder (with or without detrusor overactivity and underactivity) a real clinical syndrome? ICI-RS 2019","volume":"39","author":"Mancini","year":"2020","journal-title":"Neurourol Urodyn"},{"issue":"(Suppl 5)","key":"R32-20250504","first-page":"S46","article-title":"How can we better manage drug-resistant OAB\/DO? ICI-RS 2018","volume":"38","author":"Chermansky","year":"2019","journal-title":"Neurourol Urodyn"},{"key":"R33-20250504","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1002\/nau.22296","article-title":"Effects of percutaneous tibial nerve stimulation on adult patients with overactive bladder syndrome: a systematic review","volume":"32","author":"Moossdorff-Steinhauser","year":"2013","journal-title":"Neurourol Urodyn"},{"key":"R34-20250504","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/j.1525-1403.2012.00504.x","article-title":"Efficacy and effectiveness of percutaneous tibial nerve stimulation in the treatment of pelvic organ disorders: a systematic review","volume":"16","author":"Biemans","year":"2013","journal-title":"Neuromodulation"},{"key":"R35-20250504","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1016\/j.juro.2009.12.036","article-title":"Randomized trial of percutaneous tibial nerve stimulation versus Sham efficacy in the treatment of overactive bladder syndrome: results from the SUmiT trial","volume":"183","author":"Peters","year":"2010","journal-title":"J Urol"},{"key":"R36-20250504","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1111\/j.1464-410X.2006.06055.x","article-title":"Percutaneous tibial nerve stimulation in the treatment of refractory overactive bladder syndrome: is maintenance treatment necessary?","volume":"97","author":"van der Pal","year":"2006","journal-title":"BJU Int"},{"key":"R37-20250504","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1002\/nau.22251","article-title":"Effectiveness of percutaneous posterior tibial nerve stimulation for overactive bladder: a systematic review and meta-analysis","volume":"31","author":"Burton","year":"2012","journal-title":"Neurourol Urodyn"},{"key":"R38-20250504","first-page":"188","article-title":"Effectiveness of short term percutaneous tibial nerve stimulation for non-neurogenic overactive bladder syndrome in adults: a meta-analysis","volume":"47","author":"Wibisono","year":"2015","journal-title":"Acta Med Indones"},{"key":"R39-20250504","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.juro.2009.08.160","article-title":"Long-term durability of percutaneous tibial nerve stimulation for the treatment of overactive bladder","volume":"183","author":"MacDiarmid","year":"2010","journal-title":"J Urol"},{"key":"R40-20250504","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1002\/nau.20651","article-title":"Percutaneous tibial nerve stimulation produces effects on brain activity: study on the modifications of the long latency somatosensory evoked potentials","volume":"28","author":"Finazzi-Agr\u00f2","year":"2009","journal-title":"Neurourol Urodyn"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000027745","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T04:15:07Z","timestamp":1746332107000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000027745"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,12]]},"references-count":40,"journal-issue":{"issue":"45","published-online":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000027745","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,12]]},"assertion":[{"value":"2021-07-12","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-10-25","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}